Welcome to our dedicated page for Prophase Labs SEC filings (Ticker: PRPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Investors investigating ProPhase Labs’ blend of cutting-edge diagnostics and consumer health products usually start with one question: where in the filings can I find what matters? Whether you’re tracking COVID-19 test volume, genomics R&D spend or contract-manufacturing margins, our page maps every disclosure so you never hunt through hundreds of pages again.
Use the navigation pane to jump straight to the ProPhase Labs quarterly earnings report 10-Q filing for segment revenue detail, open the ProPhase Labs annual report 10-K simplified for long-term strategy, or scan the latest ProPhase Labs 8-K material events explained for sudden lab expansions. Each document arrives within seconds of hitting EDGAR, and our AI produces concise bullet-point summaries—understanding ProPhase Labs SEC documents with AI truly means saving hours.
Need real-time ownership data? Our alert feed captures ProPhase Labs insider trading Form 4 transactions and flags patterns in ProPhase Labs executive stock transactions Form 4. Curious about compensation? The ProPhase Labs proxy statement executive compensation tab clarifies salary, bonuses and equity grants. For event-driven traders, every headline comes with a one-click ProPhase Labs earnings report filing analysis that highlights diagnostics revenue swings, consumer product sell-through, and manufacturing capacity metrics.
From ProPhase Labs Form 4 insider transactions real-time alerts to AI-tagged risk factors, Stock Titan delivers comprehensive coverage of all SEC forms—10-K, 10-Q, 8-K, 4, S-3 and more—plus plain-language context. Explore the filings today and move from data to decision without wading through technical jargon.
ProPhase Labs filed an amended 8-K to disclose material loan agreements executed on June 22, 2025. The company entered into two identical loan arrangements:
- Two $500,000 non-convertible loans with: - CEO/Chairman Ted Karkus (related party transaction) - An unaffiliated investor
- Key loan terms: - 20% original issue discount - 10% annual interest rate - 12-month maturity - Secured but subordinate to other potential lenders up to $6M - Prepayment allowed without penalty
- Each loan includes 500,000 unvested warrants to purchase common stock at $0.60 exercise price, subject to shareholder approval of authorized share increase
The Audit Committee approved the related-party transaction with Karkus, who receives a $10,000 non-accountable expense reimbursement. The warrant issuance was made under Securities Act Section 4(a)(2) exemption and Rule 506 of Regulation D.
ProPhase Labs (Nasdaq: PRPH) filed an 8-K disclosing two identical $500,000 secured loans executed on June 22 2025 with CEO Ted Karkus (a related-party) and an unaffiliated investor.
- 20% original-issue discount; company receives $400k per loan
- 10% annual interest; 12-month maturity; prepayable anytime
- Loans are subordinate to up to $6 million of future senior debt
- Company pays the CEO a $10,000 expense reimbursement
- Issued 500,000 unvested warrants at a $0.60 strike, vesting only after shareholder approval of additional authorized shares
The Audit Committee approved the related-party terms. The warrant issuance relies on Rule 506 of Regulation D. The filing creates a new financial obligation, unregistered equity issuance, and potential dilution, affecting near-term liquidity and governance optics.
ProPhase Labs (Nasdaq: PRPH) filed an 8-K (Item 3.01 & 7.01) disclosing it remains non-compliant with Nasdaq Listing Rule 5550(a)(2) after its shares closed below $1.00 for 30 consecutive trading days. Nasdaq granted a second 180-day extension, moving the cure deadline to December 22 2025. To regain compliance, PRPH must record a closing bid price of at least $1.00 for 10 consecutive business days and receive staff confirmation. Failure to do so will trigger a delisting notice and trading suspension, with only a non-staying appeal available. The company states it is otherwise compliant with all other listing standards and is “actively monitoring” its stock price while evaluating options. A related press release was furnished as Exhibit 99.1.
ProPhase Labs (Nasdaq:PRPH) filed a routine Form 8-K disclosing the appointment of Carolina Abenante, Esq. as an independent director effective June 20, 2025. She immediately joins the Nominating & Corporate Governance Committee and becomes Chair of the Compensation Committee; the Board also intends to add her to the Audit Committee after July 19, 2025, pending shareholder approval. Abenante, 55, is considered independent and financially literate under Nasdaq and SEC rules and brings tax, finance and legal expertise from prior executive roles at NYIAX and other AdTech firms. Director compensation matches existing non-employee terms: $48,000 annual cash retainer plus participation in the Director’s Equity Plan. The company reported no related-party transactions or family relationships.
ProPhase Labs (NASDAQ:PRPH) filed its 2025 Definitive Proxy Statement for the Annual Meeting of Stockholders scheduled for July 18, 2025 at 4:00 p.m. ET in Lynbrook, NY.
Stockholders will vote on four routine items:
- Proposal 1: Elect four director nominees to serve until the 2026 meeting.
- Proposal 2: Ratify Fruci & Associates II, PLLC as independent auditor for fiscal 2025.
- Proposal 3: Advisory Say-on-Pay vote on 2024 executive compensation.
- Proposal 4: Advisory vote on the frequency of future Say-on-Pay votes.
The record date is June 20, 2025; only shareholders of record at that close of business may vote. The proxy materials and the company’s 2024 Form 10-K are available at www.proxyvote.com. Holders may vote by proxy in advance or in person. No contested matters, major transactions, or material changes are disclosed.
FAQ
What is the current stock price of Prophase Labs (PRPH)?
What is the market cap of Prophase Labs (PRPH)?
What are the main business segments of ProPhase Labs Inc?
How does ProPhase Labs generate revenue?
What role does technology play in ProPhase Labs' operations?
How does the company differentiate itself in the competitive healthcare market?
What are the core competencies of ProPhase Labs?
Who are the primary customers of ProPhase Labs?
